Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment

摘要

Treatment options are limited for patients with cancer and renal impairment. In a subset analysis of patients with advanced nonesmall-cell lung cancer (NSCLC) and renal impairment in a phase III trial of nab-paclitaxel plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin, nab-P/C was well tolerated and offered a feasible treatment option for patients with renal impairment and advanced NSCLC.